Sorted By Test Name - Mayo Medical Laboratories

HIBS
83261
HAKE
82348
Haemophilus influenzae Type B Antibody, IgG, Serum
Clinical Information: Haemophilus influenzae type B (HIB) is an encapsulated gram-negative
cocco-bacillary bacterium that can cause devastating disease in young children including meningitis,
bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis. One of the great advances in modern
medicine has been the development of an effective vaccine against HIB. A patient's immunological
response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this enzyme
immunoassay (EIA) technique.
Useful For: Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B
(HIB) vaccine Assessing immunity against HIB As an aid in the evaluation of immunodeficiency
Interpretation: An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15
mg/L is generally accepted as the minimum level for protection at a given time, however, it does not
confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0
mg/L postimmunization.(2) Furthermore, studies have shown that the response to HIB vaccine is
age-related. By testing pre- and postvaccination patient serum specimens, this test may be used to aid
diagnosis of immunodeficiency.
Reference Values:
> or =0.15 mg/L
Clinical References: 1. Berger M: Immunoglobulin G subclass determination in diagnosis and
management of antibody deficiency syndromes. J Pediatr 1987;110(2):325-328 2. Peltola H, Kayhty H,
Virtanen M, et al: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular
polysaccharide vaccine. N Engl J Med 1984;310(24):1561-1566
Hake, Fish, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
immune response to allergen(s) that may be associated with allergic disease. The allergens chosen for
testing often depend upon the age of the patient, history of allergen exposure, season of the year, and
clinical manifestations. In individuals predisposed to develop allergic disease(s), the sequence of
sensitization and clinical manifestations proceed as follows: eczema and respiratory disease (rhinitis and
bronchospasm) in infants and children less than 5 years due to food sensitivity (milk, egg, soy, and wheat
proteins) followed by respiratory disease (rhinitis and asthma) in older children and adults due to
sensitivity to inhalant allergens (dust mite, mold, and pollen inhalants).
Useful For: Testing for IgE antibodies may be useful to establish the diagnosis of an allergic disease
and to define the allergens responsible for eliciting signs and symptoms. Testing also may be useful to
identify allergens which may be responsible for allergic disease and/or anaphylactic episode, to confirm
sensitization to particular allergens prior to beginning immunotherapy, and to investigate the specificity of
allergic reactions to insect venom allergens, drugs, or chemical allergens.
Interpretation: Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased
likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be
responsible for eliciting signs and symptoms. The level of IgE antibodies in serum varies directly with the
concentration of IgE antibodies expressed as a class score or kU/L.
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 850